Michigan SB616: Civil procedure: civil actions; civil actions against certain opioid litigation settlement defendants; prohibit. Amends secs. 2 & 3 of 2022 PA 85 (MCL 691.1672 & 691.1673).

What the bill says

An act to amend 2022 PA 85, entitled “An act to prohibit the commencement of civil actions relating to opioids by certain governmental officers and entities,” by amending sections 2 and 3 (MCL 691.1672 and 691.1673), as amended by 2023 PA 228.

From the chaptered text, July 23, 2026:

AN ACT to amend 2022 PA 85, entitled “An act to prohibit the commencement of civil actions relating to opioids by certain governmental officers and entities,” by amending sections 2 and 3 (MCL 691.1672 and 691.1673), as amended by 2023 PA 228. The People of the State of Michigan enact: Sec. 2. As used in this act: (a) “Allergan settlement” means the master settlement agreement arising out of the MDL and entered into by this state with Allergan Pharmaceuticals. (b) “Alvogen settlement” means the master settlement agreement arising out of the MDL and entered into by this state with Alvogen, Incorporated. (c) “Amneal settlement” means the master settlement agreement arising out of the MDL and entered into by this state with Amneal Pharmaceuticals, LLC. (d) “Apotex settlement” means the master settlement agreement arising out of the MDL and entered into by this state with Apotex Corporation. (e) “CVS settlement” means the master settlement agreement arising out of the MDL and entered into by this state with CVS Pharmacy. (f) “Distributor settlement” means the master settlement agreement arising out of the MDL and entered into by this state with AmerisourceBergen Corporation, Cardinal Health, Inc., and McKesson Corporation. (g) “Hikma settlement” means the master settlement agreement arising out of the MDL and entered into by this state with Hikma Pharmaceuticals USA, Incorporated. …

Read the full official text

Sponsors

• Santana, Sylvia (D, 2) · primary sponsor

Latest actions

1. July 29, 2026: ASSIGNED PA 0049'26 WITH IMMEDIATE EFFECT
2. July 23, 2026: FILED WITH SECRETARY OF STATE 7/23/2026 11:32 AM
3. July 21, 2026: APPROVED BY GOVERNOR 7/21/2026 1:28 PM
4. July 14, 2026: PRESENTED TO GOVERNOR 7/14/2026 11:08 AM
5. July 3, 2026: ORDERED ENROLLED
6. July 3, 2026: FULL TITLE AGREED TO
7. July 3, 2026: GIVEN IMMEDIATE EFFECT
8. July 3, 2026: returned to Senate
9. July 3, 2026: inserted full title
10. July 3, 2026: passed; given immediate effect Roll Call #294 Yeas 102 Nays 6 Excused 0 Not Voting 2

Votes

• passed; given immediate effect (July 3, 2026): 102 yea, 6 nay, passed
• Reported With Recommendation Without Amendment (April 15, 2026): 10 yea, 0 nay, passed
• Reported Favorably Without Amendment 11/13/2025 (December 2, 2025): 7 yea, 0 nay, passed
• PASSED (December 2, 2025): 36 yea, 1 nay, passed

Common questions

What is SB616?

SB616 is a bill in the Michigan Legislature (103rd Legislature): Civil procedure: civil actions; civil actions against certain opioid litigation settlement defendants; prohibit. Amends secs. 2 & 3 of 2022 PA 85 (MCL 691.1672 & 691.1673).

What does SB616 do?

In its own words: An act to amend 2022 PA 85, entitled “An act to prohibit the commencement of civil actions relating to opioids by certain governmental officers and entities,” by amending sections 2 and 3 (MCL 691.1672 and 691.1673), as amended by 2023 PA 228.

What is the status of SB616?

Signed into law as of July 29, 2026. Latest action: ASSIGNED PA 0049'26 WITH IMMEDIATE EFFECT (July 29, 2026).

Who sponsored SB616?

Santana, Sylvia (D, 2).

Where is the official record for SB616?

On the Michigan Legislature website: https://www.legislature.mi.gov/Bills/Bill?ObjectName=2025-SB-0616